1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Xcorporeal, Inc.

Xcorporeal, Inc.

XCRP
Xcorporeal, Inc.US flagOther OTC
0.00
USD
- -
- -
1,515.00Market Cap
1997 Y
1998 Y
1999 Y
2000 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
TTM
Revenue per Share
21.74
5.38
8.86
1.7
5.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-30.67
-11.79
-13.69
-31.25
-98.75
-1.23
-7.18
1.13
-3.57
-0.56
-0.67
-1.2
-1.57
-0.2
Free Cash Flow per Basic Share
-27.37
-8.87
-10.87
-4.53
-15.19
-0.13
-0.63
-0.21
-0.19
-0.04
0.01
-0.78
-0.87
-0.36
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-39.54
-44.04
67.26
-58.08
-633.95
-60.06
-61.37
-55.28
-53.52
-53.33
-0.69
-1.52
-3.05
-3.21
Tangible Book Value per Share
-6.93
-10.62
22.64
3.25
20.77
0.66
-3.47
-1.26
-4.54
-4.81
3.88
1.07
-0.14
-0.21
Basic Weighted Avg Shares
- -
- -
- -
1
- -
1
1
1
1
1
7
14
15
15
Sales/Revenue/Turnover
5
2
4
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-134.8
-205.92
-111.36
-375.93
-758.94
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
2
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-8
-4
-7
-24
-8
-1
-7
1
-4
-1
-4
-17
-23
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-141.11
-218.35
-152.27
-1,830.68
-1,762.59
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-3
-3
8
- -
-2
-2
-3
-1
-5
-6
25
15
-1
-3
LT Debt
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
3
1
11
2
2
1
-3
-1
-5
-6
25
15
-2
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'09
Jun'09
Sep'09
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
5
4
2

Working Capital

FRC

•

in mil. unless spec.
Mar'09
Jun'09
Sep'09
Total Current Assets
2
1
1
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
4
Payables & Accruals
4
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-130.03%
-77.52%
-113.38%
Free Cash Flow
-1,668.06%
-3,374.94%
15.12%
Net Income, GAAP
87.34%
68.59%
34.63%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
-0.34
-0.2
-0.32
- -
-1.2
2008
-0.44
-0.36
-0.76
- -
-1.57
2009
-0.01
-0.07
-0.1
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Victor Gura
Full Time Employees
24
Sector
Healthcare
Industry
Medical - Specialties
Address
80 Empire Drive Lake Forest CA United States of America
IPO Date
Jan 3, 2000
Website
xcorporeal.com
Similar Companies
Theralase Technologies Inc. (TLT.V)
United American Healthcare Corporation (UAHC)
Lancer Orthodontics, Inc. (LANZ)
Bayer AG (BAYNN.MX)
KMS Medisurgi Limited (KMSMEDI.BO)
SpectraScience, Inc. (SCIE)
Business
Xcorporeal, Inc. Xcorporeal, Inc. (XCRP) operates as a shell company in the process of liquidation and dissolution under a plan adopted by its board of directors on February 4, 2010, with all assets transferred to the Xcorporeal, Inc. Liquidating Trust managed by XCRLT, LLC. Previously, the medical device company, founded in 2001 and headquartered at 80 Empire Drive, Lake Forest, California, developed an innovative extracorporeal platform technology for devices replacing functions of human organs such as kidneys, including home and hospital renal replacement therapy systems, ultrafiltration devices, and a wearable artificial kidney. Its core offerings encompassed prototype systems applying modern electronics and engineering to reduce size, cost, and power needs of conventional extracorporeal therapies like dialysis; the company targeted healthcare markets in the United States with no current active operations or geographic expansions beyond domestic focus. In December 2009, Xcorporeal signed an asset purchase agreement with National Quality Care, Inc., a Fresenius Medical Care North America affiliate, for substantially all assets including supersorbent dialysis technology, granting back a perpetual worldwide license option for non-renal healthcare uses following regulatory approval; this transaction maximized shareholder value amid strategic reviews of mergers, financing, and independence, effectively ceasing development activities thereafter. No further partnerships, acquisitions, product launches, funding, or operational changes have occurred since the 2010 liquidation initiation, with the entity maintaining a minimal market capitalization and no analyst coverage or revenue generation.

Company News

APIChatGPT

  • defenseworld.net

    IQVIA (NYSE:IQV) and Xcorporeal (OTCMKTS:XCRP) Head-To-Head Survey